Joshua Fleischman
Analyst
TD Cowen
Equibles does not estimate personal net worth.
About Joshua Fleischman
Joshua Fleischman is recorded as Analyst at TD Cowen. Joshua Fleischman has spoken on 4 earnings calls across 2 companies, most recently for Sarepta Therapeutics, Inc. on November 5, 2026. Those appearances were for Sarepta Therapeutics, Inc. (SRPT) and Krystal Biotech, Inc. (KRYS). The companies whose calls Joshua Fleischman spoke on are classified in the Healthcare sector.
Joshua Fleischman on recent calls
“Curious, what needs to be done prior to releasing the upcoming MAD data? And once that data is presented, are there any gating items to pivotal trial start? And then one more to tag on to that.”
“I wanted to start by asking, what is the current progress of Cohort 8 recruitment, and are there any current timelines to enrollment completion? On the call, you guys also mentioned DM1 functional data, but what FSHD functional data will be included in the second half 26 data release?”
“Just curious, was patient compliance also the major factor required to get at-home self-dosing for 803 and ocular deb? And what was the differentiating factor that resulted in the three times a week dosing schedule for 803 and the once daily dosing schedule for 801?”
“How do you expect for drug holidays to factor into the original guidance of 720 U.S. patients initiating IGEVAC? And on Europe, how should we think about pricing, and what's important to the country's health technology assessments?”
Affiliation history
-
TD Cowen
Analyst
Transcript header (unverified)
Current